A phase 2 study of S-812217 in patients with major depressive disorder

SHIONOGI & CO., LTD.0 个研究点目标入组 240 人开始时间: 2020年4月28日最近更新: 2023年10月17日

试验速览

暂无简介。

•Patients who have been interviewed using Mini-International Neuropsychiatric. Interview (M.I.N.I) and diagnosed with major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5) and met the following 2 conditions:
•- The current episode is ongoing for at least 8 weeks prior to the day of signing the informed consent form
•- Duration of current episode is <= 12 months prior to signing the informed consent

•- Patients with treatment-resistant depression (defined as persistent depressive symptoms despite treatment with adequate doses of antidepressants [excluding antipsychotics] within the current depressive episode from two or more different classes for at least 4 weeks of treatment). (The Massachusetts General Hospital Antidepressant Treatment Response Questionnaire [MGH ATRQ] will be used for the evaluation)
•- Patients who have been treated with devices such as vagal nerve stimulation, electroconvulsive therapy, and transcranial magnetic stimulation within the current depressive episode.

发起方